Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/88054
Title:
Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.
Authors:
Michelagnoli, M P; Lewis, I J; Gattamaneni, Rao; Bailey, C C; Lashford, Linda S
Abstract:
Fifteen patients with relapsed osteosarcoma were treated with an intensive combination chemotherapy schedule. Ifosfamide 2.5 g m(-2) daily and etoposide 150 mg m(-2) daily coincidentally for 3 days and high-dose methotrexate 8 g m(-2) (with folinic acid rescue) on days 10-14 in a planned 21 -day cycle. Feasibility, toxicity and response to this alternative combination for the treatment of relapsed osteosarcoma was assessed. There were 98 evaluable cycles for toxicity and tolerability. The majority of cycles were well tolerated. Haematological toxicity of grade 3/4 (common toxicity criteria) was seen in all courses. Renal tubular loss of electrolytes, particularly magnesium, occurred in 71% of cycles. Thirteen per cent of cycles were repeated within 21 days and 61% within 28 days. In the thirteen patients evaluable for response, a partial response rate of 31% was seen after two cycles. However, patients with stable disease continued on therapy, and an overall consequent response rate of 62% was observed. Four patients were alive with no evidence of disease at 8-74 months. Three are alive with disease (at 8-19 months). There were six deaths, all disease related. This regimen exhibits an encouraging response rate in a group of children with poor prognosis disease, with a tolerable toxicity profile.
Affiliation:
Paediatric Haematology and Oncology Unit, St James University Hospital, Leeds, UK.
Citation:
Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma. 1999, 79 (7-8):1174-8 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Mar-1999
URI:
http://hdl.handle.net/10541/88054
DOI:
10.1038/sj.bjc.6690187
PubMed ID:
10098754
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorMichelagnoli, M Pen
dc.contributor.authorLewis, I Jen
dc.contributor.authorGattamaneni, Raoen
dc.contributor.authorBailey, C Cen
dc.contributor.authorLashford, Linda Sen
dc.date.accessioned2009-12-15T16:32:12Z-
dc.date.available2009-12-15T16:32:12Z-
dc.date.issued1999-03-
dc.identifier.citationIfosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma. 1999, 79 (7-8):1174-8 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid10098754-
dc.identifier.doi10.1038/sj.bjc.6690187-
dc.identifier.urihttp://hdl.handle.net/10541/88054-
dc.description.abstractFifteen patients with relapsed osteosarcoma were treated with an intensive combination chemotherapy schedule. Ifosfamide 2.5 g m(-2) daily and etoposide 150 mg m(-2) daily coincidentally for 3 days and high-dose methotrexate 8 g m(-2) (with folinic acid rescue) on days 10-14 in a planned 21 -day cycle. Feasibility, toxicity and response to this alternative combination for the treatment of relapsed osteosarcoma was assessed. There were 98 evaluable cycles for toxicity and tolerability. The majority of cycles were well tolerated. Haematological toxicity of grade 3/4 (common toxicity criteria) was seen in all courses. Renal tubular loss of electrolytes, particularly magnesium, occurred in 71% of cycles. Thirteen per cent of cycles were repeated within 21 days and 61% within 28 days. In the thirteen patients evaluable for response, a partial response rate of 31% was seen after two cycles. However, patients with stable disease continued on therapy, and an overall consequent response rate of 62% was observed. Four patients were alive with no evidence of disease at 8-74 months. Three are alive with disease (at 8-19 months). There were six deaths, all disease related. This regimen exhibits an encouraging response rate in a group of children with poor prognosis disease, with a tolerable toxicity profile.en
dc.language.isoenen
dc.subjectBone Canceren
dc.subject.meshAdolescent-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBone Neoplasms-
dc.subject.meshChild-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshEtoposide-
dc.subject.meshFeasibility Studies-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshMale-
dc.subject.meshMethotrexate-
dc.subject.meshOsteosarcoma-
dc.subject.meshRecurrence-
dc.subject.meshRetrospective Studies-
dc.titleIfosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.en
dc.typeArticleen
dc.contributor.departmentPaediatric Haematology and Oncology Unit, St James University Hospital, Leeds, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.